→ C4 Therapeutics has raided the Novartis Institutes of Biomedical Research for its chief medical officer. The biotech reported today that it’s hired on Adam Crystal for the spot, following a stint as a senior director at NIBR. C4 is one of several biotechs working on protein degraders, which has also been a keen interest of NIBR chief Jay Bradner. “Dr. Crystal’s deep understanding of the science of targeted protein degradation, coupled to his proven clinical leadership and understanding of the patient community, will be instrumental to advancing C4T’s pipeline,” said Andy Phillips, the CEO of C4.
→ Roche has gotten the OK to market Hemlibra to a much broader group of patients in Europe, nabbing another big piece of the blockbuster picture it’s painted for the hemophilia drug. Hemophilia A patients of all ages, whether they have developed factor VIII inhibitors or not, can now routinely take Hemlibra to prevent bleeding episodes, with a choice of dosing options between once weekly, every two weeks or every four weeks. The European green light comes several months after the FDA also endorsed this expanded use of Hemlibra. “Today’s approval is a landmark moment as Hemlibra is the first new class of treatment for people with severe haemophilia A without inhibitors in nearly 20 years,” said Sandra Horning, Roche’s global head of development, in a statement.
→ The Gates Foundation is going back to Canadian antibody discovery shop AbCellera for a collaboration on infectious diseases. With $4.8 million in funding, AbCellera and Gates-backed scientists will look into both vaccines and antibody-based treatments targeting HIV, malaria and tuberculosis among others.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription